An Expert Discussion of Testosterone Nadir and Clinical Outcomes in Patients with Advanced Prostate Cancer: A Post Hoc Analysis of Triptorelin Pamoate Phase III Studies
In a program supported by Verity Pharmaceuticals, Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center and Chief Medical Officer, Strategic Growth and Pharmacy, GenesisCare US, Myrtle Beach, South Carolina, and Laurence Klotz, MD, FRCSC, Professor of Surgery at the University of Toronto and the Sunnybrook Chair of Prostate Cancer Research in Toronto, Ontario, Canada, discuss Dr. Klotz’s paper published in January 2024 entitled, “Testosterone Nadir and Clinical Outcomes in Patients with Advanced Prostate Cancer: Post Hoc Analysis of Triptorelin Pamoate Phase III Studies.”
Dr. Klotz describes the objective of the study was to evaluate whether low nadir testosterone during treatment with triptorelin pamoate, a luteinizing hormone-releasing hormone (LHRH) agonist, is associated with improved clinical outcomes in patients with advanced prostate cancer using a retrospective analysis of clinical trial data. He discusses how data was pooled from three prospective, 9–12-month Phase III studies of triptorelin monotherapy in patients with advanced prostate cancer
Dr. Klotz also addresses the overall survival (OS) and disease-specific survival (DSS) by testosterone suppression group, assessed by Kaplan–Meier analysis with a log-rank test. He concludes the review by describing how, in the sample size comprised of 592 patients, low nadir testosterone achieved during treatment with the LHRH agonist triptorelin was associated with improved OS and DSS in patients with advanced prostate cancer.
Dr. Klotz and Dr. Shore then discuss the impact of the results from this trial and the potential future direction of treatment options for men with prostate cancer.
Supported by
